Inovio Pharmaceu SEC Filings

Inovio Pharmaceuticals (INO) launched a primary offering of 13,158,000 shares of common stock via a prospectus supplement. The public offering price is $1.90 per share, implying gross proceeds of $25,000,200 and net proceeds of $23,500,188 after underwriting discounts and before expenses. The company granted underwriters a 30‑day option to purchase up to 1,973,700 additional shares at the public price, less discounts.

Inovio estimates approximately $23 million in net proceeds (or approximately $26.5 million if the option is exercised in full). The company plans to use the funds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. Shares outstanding were 53,571,675 as of September 30, 2025; the company states shares outstanding would be 66,729,675 immediately after this offering (or 68,703,375 if the option is fully exercised). Inovio expects that cash and this offering’s net proceeds will fund operations into the third quarter 2026.

Piper Sandler is the sole bookrunner. The Nasdaq Capital Market listing remains “INO,” and the last reported sale price on November 10, 2025 was $2.15 per share.

Inovio Pharmaceuticals launched a primary offering of common stock via a preliminary prospectus supplement under its effective shelf registration. Piper Sandler is bookrunning the deal, and the company granted the underwriters a 30‑day option to purchase additional shares at the public offering price, less discounts and commissions.

Inovio plans to use the proceeds primarily to prepare for a potential commercial launch of INO‑3107, if approved, to advance its clinical pipeline, and for general corporate purposes. The company reported that it completed submission of a Biologics License Application for INO‑3107 under the FDA’s accelerated approval program and requested priority review, targeting file acceptance by the end of 2025. Inovio’s common stock trades on Nasdaq as “INO,” and it is classified as a “smaller reporting company.”

Inovio Pharmaceuticals (INO) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1.

Per Item 2.02 and General Instruction B.2, this information is being furnished and is not deemed filed under the Exchange Act. The report is dated November 10, 2025 and was signed by CFO Peter Kies.

Inovio Pharmaceuticals (INO) reported Q3 2025 results with a net loss of $45.5 million (basic/diluted EPS $(0.87)) versus a loss of $25.2 million a year ago. Operating expenses declined year over year as research and development was $13.3 million (vs. $18.7 million) and general and administrative was $7.9 million (vs. $8.6 million). A $22.5 million increase in the fair value of warrant liabilities drove a sizeable other expense.

Cash and cash equivalents were $36.6 million and short-term investments were $14.2 million, totaling $50.8 million at September 30, 2025. Stockholders’ equity was $(7.7) million, down from $68.5 million at year-end 2024, reflecting cumulative losses and warrant liability remeasurement. Management states available liquidity is expected to support planned operations into the second quarter of 2026, and there is substantial doubt about the ability to continue as a going concern beyond the first quarter of 2026. The company closed a July 2025 equity-and-warrants financing with net proceeds of $22.4 million.

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices, with lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). In a completed Phase 1/2 trial of INO-3107, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following treatment versus the year prior.

For the quarter and six months ended June 30, 2025, the company reported net losses of $23.5 million and $43.2 million, respectively, with net loss per share of $0.61 for the quarter and $1.12 year-to-date. Cash and cash equivalents were $24.35 million and short-term investments were $23.20 million (combined $47.5 million). Working capital was $21.0 million, total assets $68.24 million, total stockholders' equity $28.53 million, and accumulated deficit $1.773 billion.

The company disclosed substantial doubt about its ability to continue as a going concern beyond Q2 2026, but closed a July 7, 2025 underwritten public offering that generated $22.5 million of net proceeds. Management resolved a prior manufacturing issue for a CELLECTRA disposable component and completed Design Verification testing.